PRA Health Sciences, Inc. is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. Its services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. It provides its clients with clinical development service offerings, which includes both traditional, project-based Phase I through Phase IV services, as well as embedded and functional outsourcing services. As of December 31, 2016, its clinical development platform included approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East. The Company's service offerings include product registration, strategic solutions and early development services.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Laboratories & Research
- Sub-Industry: N/A
- Symbol: NASDAQ:PRAH
- CUSIP: N/A
- Web: www.prahs.com
- Market Cap: $4.47 billion
- Outstanding Shares: 62,471,000
- 50 Day Moving Avg: $66.39
- 200 Day Moving Avg: $59.75
- 52 Week Range: $39.25 - $72.40
Sales & Book Value:
- Trailing P/E Ratio: 42.71
- Foreward P/E Ratio: 19.22
- P/E Growth: 1.19
- Annual Revenue: $1.63 billion
- Price / Sales: 2.74
- Book Value: $12.45 per share
- Price / Book: 5.74
- EBIDTA: $262.56 million
- Net Margins: 4.86%
- Return on Equity: 21.25%
- Return on Assets: 6.86%
- Debt-to-Equity Ratio: 1.20%
- Current Ratio: 1.25%
- Quick Ratio: 1.25%
- Average Volume: 536,753 shs.
- Beta: 0.54
- Short Ratio: 3.1
Frequently Asked Questions for PRA Health Sciences (NASDAQ:PRAH)
What is PRA Health Sciences' stock symbol?
PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."
How were PRA Health Sciences' earnings last quarter?
PRA Health Sciences Inc (NASDAQ:PRAH) posted its earnings results on Tuesday, April, 25th. The company reported $0.60 EPS for the quarter, beating the Zacks' consensus estimate of $0.58 by $0.02. The firm had revenue of $427.08 million for the quarter, compared to analysts' expectations of $426.81 million. PRA Health Sciences had a return on equity of 21.25% and a net margin of 4.86%. The company's quarterly revenue was up 14.7% on a year-over-year basis. During the same period last year, the firm earned $0.55 EPS. View PRA Health Sciences' Earnings History.
What guidance has PRA Health Sciences issued on next quarter's earnings?
PRA Health Sciences updated its FY17 earnings guidance on Tuesday, April, 25th. The company provided EPS guidance of $3.08-3.18 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.13. The company issued revenue guidance of $1.795-1.835 billion, compared to the consensus revenue estimate of $1.84 billion.
Where is PRA Health Sciences' stock going? Where will PRA Health Sciences' stock price be in 2017?
6 brokers have issued 12 month target prices for PRA Health Sciences' stock. Their forecasts range from $47.00 to $72.50. On average, they expect PRA Health Sciences' share price to reach $61.75 in the next year. View Analyst Ratings for PRA Health Sciences.
What are analysts saying about PRA Health Sciences stock?
Here are some recent quotes from research analysts about PRA Health Sciences stock:
- 1. According to Zacks Investment Research, "PRA Health Sciences, Inc. operates as a global contract research organizations providing outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in the areas of cardio-metabolic, biosimilars, infectious diseases, immunology, neurology and psychiatry, oncology and hematology, rare diseases, and respiratory needs. The Company engages in bioanalytical laboratory, clinical pharmacology, clinical development, strategic solutions, post marketing research, clinical informatics, clinical diagnostics, and safety and risk management activities. PRA Health Sciences, Inc. is based in Raleigh, North Carolina. " (3/2/2017)
- 2. KeyCorp analysts commented, "By our models, the strength of PRAH's backlog (up 16 percent YOY) and bookings (1.25xR4Q) sets up for above-consensus performance," analyst Donald Hooker wrote in a note.Hooker expects constant currency revenue growth of 13.8 percent in 2016 (consensus: 12.7 percent) and 10.9 percent in 2017 (consensus: 9.5 percent), which should boost profit margins. The analyst forecast 2016 EPS of $2.46 (consensus: $2.43), and 2017 EPS of $2.96 (consensus: $2.82).Related Link: Raymond James Sees Lingering Risks At OraSure, DowngradesEven assuming a modest slowdown in backlog conversion, we think revenues should come in toward the high end of management's 2016 guidance with significant backlog left over for a strong 2017 and 2018," Hooker highlighted.Other Expectations For PRA HealthThe analyst also models EBITDA growth of almost 13 percent in 2017, which is well above the peer group average about 10 percent.In addition, the analyst noted that investors under appreciate the bookings strength from PRA Health's investments in analytics that include Predictivv cloud-based technology platform and its recent acquisition of Nextrials, an electric data capture (EDC) vendor. Hooker said, "Management has been developing retroactive and predictive algorithms over the past eight years, and we believe this work may now be starting to show up in bookings."[M]anagement has recently addressed PRAH's indebtedness and ownership concentration, which reduces two of the largest overhangs on the shares, in our view," (6/13/2016)
Are investors shorting PRA Health Sciences?
PRA Health Sciences saw a decline in short interest in April. As of April 28th, there was short interest totalling 1,186,518 shares, a decline of 24.3% from the April 13th total of 1,566,748 shares. Based on an average daily volume of 712,334 shares, the short-interest ratio is currently 1.7 days. Approximately 3.0% of the company's shares are sold short.
Who are some of PRA Health Sciences' key competitors?
Some companies that are related to PRA Health Sciences include PerkinElmer (PKI), Bio-Rad Laboratories (BIO), DexCom (DXCM), Icon Plc (ICLR), Charles River Laboratories Intl. (CRL), VWR Corp (VWR), Bruker (BRKR), Alere (ALR), PAREXEL International (PRXL), EXACT Sciences (EXAS), WuXi PharmaTech (Cayman) (WX), Accelerate Diagnostics (AXDX), Abaxis (ABAX), Genomic Health (GHDX), Analogic (ALOG), BioTelemetry (BEAT), Heska Corp (HSKA) and China Cord Blood Corp (CO).
When did PRA Health Sciences IPO?
(PRAH) raised $306 million in an initial public offering (IPO) on Thursday, November 13th 2014. The company issued 17,000,000 shares at $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.
Who owns PRA Health Sciences stock?
PRA Health Sciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.46%), BlackRock Inc. (4.57%), Acadian Asset Management LLC (3.49%), MARSHALL WACE ASIA Ltd (2.04%), Marshall Wace North America L.P. (2.04%) and Eagle Asset Management Inc. (1.82%). Company insiders that own PRA Health Sciences stock include Colin Shannon, David W Dockhorn, Linda Baddour and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.
Who sold PRA Health Sciences stock? Who is selling PRA Health Sciences stock?
PRA Health Sciences' stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Morgan Stanley, TimesSquare Capital Management LLC, Hood River Capital Management LLC, FMR LLC, Point72 Asset Management L.P., King Luther Capital Management Corp and Columbia Wanger Asset Management LLC. Company insiders that have sold PRA Health Sciences stock in the last year include Colin Shannon, David W Dockhorn and Linda Baddour. View Insider Buying and Selling for PRA Health Sciences.
Who bought PRA Health Sciences stock? Who is buying PRA Health Sciences stock?
PRA Health Sciences' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Wells Fargo & Company MN, Ameriprise Financial Inc., Mesirow Financial Investment Management Equity Management, Renaissance Technologies LLC and Prudential Financial Inc.. View Insider Buying and Selling for PRA Health Sciences.
How do I buy PRA Health Sciences stock?
Shares of PRA Health Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of PRA Health Sciences stock cost?
One share of PRA Health Sciences stock can currently be purchased for approximately $71.50.
Earnings History for PRA Health Sciences (NASDAQ:PRAH)Earnings History by Quarter for PRA Health Sciences (NASDAQ:PRAH)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/25/2017||Q1 2017||$0.58||$0.60||$426.81 million||$427.08 million||View||N/A|
|2/22/2017||Q4 2016||$0.64||$0.71||$405.04 million||$413.61 million||View||N/A|
|11/2/2016||Q316||$0.64||$0.64||$394.87 million||$399.80 million||View||N/A|
|7/28/2016||Q2||$0.59||$0.63||$381.25 million||$394.20 million||View||Listen|
|4/27/2016||Q116||$0.53||$0.55||$372.21 million||$372.30 million||View||Listen|
|2/24/2016||Q4||$0.49||$0.59||$353.42 million||$428.90 million||View||Listen|
|11/2/2015||Q3||$0.45||$0.52||$346.05 million||$345.10 million||View||Listen|
|7/27/2015||Q215||$0.40||$0.47||$336.74 million||$336.50 million||View||Listen|
|5/6/2015||Q115||$0.31||$0.41||$329.80 million||$332.00 million||View||Listen|
|2/18/2015||Q414||$0.30||$0.35||$323.50 million||$370.00 million||View||Listen|
Earnings Estimates for PRA Health Sciences (NASDAQ:PRAH)
2017 EPS Consensus Estimate: $3.01
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for PRA Health Sciences (NASDAQ:PRAH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for PRA Health Sciences (NASDAQ:PRAH)
Insider Ownership Percentage: 2.50%Insider Trades by Quarter for PRA Health Sciences (NASDAQ:PRAH)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|4/17/2017||Linda Baddour||VP||Sell||196,393||$63.59||$12,488,630.87|| |
|3/28/2017||Colin Shannon||CEO||Sell||50,000||$64.00||$3,200,000.00|| |
|3/27/2017||David W Dockhorn||Insider||Sell||85,182||$62.00||$5,281,284.00|| |
|2/23/2017||Colin Shannon||CEO||Sell||100,000||$61.50||$6,150,000.00|| |
|8/22/2016||Colin Shannon||CEO||Sell||113,133||$51.57||$5,834,268.81|| |
|8/15/2016||Linda Baddour||VP||Sell||69,380||$52.00||$3,607,760.00|| |
|8/12/2016||David W. Dockhorn||VP||Sell||107,257||$49.00||$5,255,593.00|| |
|5/6/2016||Linda Baddour||CFO||Sell||92,308||$46.70||$4,310,783.60|| |
|5/6/2016||Pra Investors L.P. Kkr||Major Shareholder||Sell||4,907,692||$46.70||$229,189,216.40|| |
|3/8/2016||Colin Shannon||CEO||Sell||77,019||$42.26||$3,254,822.94|| |
|3/8/2016||Linda Baddour||CFO||Sell||93,000||$42.26||$3,930,180.00|| |
|3/8/2016||Pra Investors L.P. Kkr||Major Shareholder||Sell||4,829,981||$42.26||$204,114,997.06|| |
Headline Trends for PRA Health Sciences (NASDAQ:PRAH)
Latest Headlines for PRA Health Sciences (NASDAQ:PRAH)
|PRA Health Sciences Named International Clinical Research Company of the Year|
finance.yahoo.com - May 22 at 6:28 PM
|PRA Health Sciences Inc (PRAH) Receives Consensus Rating of "Buy" from Analysts|
www.americanbankingnews.com - May 22 at 12:24 PM
|PRA Health Sciences Inc (PRAH) Short Interest Update|
www.americanbankingnews.com - May 13 at 8:16 AM
|Biopharmaceutical Services Stock Continues To Test New Buy Zone|
finance.yahoo.com - May 12 at 8:05 PM
|Delmar Pharma (DMPI) Formalizes Collaboration with PRA Health (PRAH) for Phase 3 Trial of VAL-083 in GBM|
www.streetinsider.com - May 12 at 8:11 AM
|PRAH Crosses Above Average Analyst Target|
www.nasdaq.com - May 12 at 8:11 AM
|DelMar Formalizes Collaboration with PRA Health Sciences for Phase 3 Trial of VAL-083 in Recurrent Glioblastoma Multiforme (GBM)|
finance.yahoo.com - May 11 at 8:36 AM
|PRA Health Sciences Announces The Center for Pediatric Clinical Development|
finance.yahoo.com - May 4 at 7:31 PM
|PRA Health Sciences Inc (PRAH) Expected to Announce Quarterly Sales of $447.6 Million|
www.americanbankingnews.com - May 4 at 12:00 PM
|PRA Health Sciences (PRAH) Getting Favorable News Coverage, Analysis Shows|
www.americanbankingnews.com - May 2 at 10:02 PM
|$0.73 Earnings Per Share Expected for PRA Health Sciences Inc (PRAH) This Quarter|
www.americanbankingnews.com - May 2 at 8:00 PM
|PRA Health Sciences Named Clinical Research Company of the Year|
finance.yahoo.com - May 2 at 10:09 AM
|ETFs with exposure to PRA Health Sciences, Inc. : May 1, 2017|
finance.yahoo.com - May 1 at 6:33 PM
|William Blair Analysts Raise Earnings Estimates for PRA Health Sciences Inc (PRAH)|
www.americanbankingnews.com - May 1 at 1:44 PM
|Q3 2017 Earnings Estimate for PRA Health Sciences Inc Issued By KeyCorp (PRAH)|
www.americanbankingnews.com - May 1 at 8:54 AM
|Q2 2017 EPS Estimates for PRA Health Sciences Inc (PRAH) Decreased by Analyst|
www.americanbankingnews.com - May 1 at 7:42 AM
|PRA Health Sciences (PRAH) Getting Favorable Press Coverage, Report Finds|
www.americanbankingnews.com - April 29 at 4:47 PM
|PRA Health Sciences Inc (PRAH) Stock Rating Reaffirmed by Jefferies Group LLC|
www.americanbankingnews.com - April 29 at 1:05 AM
|FY2017 EPS Estimates for PRA Health Sciences Inc Increased by William Blair (PRAH)|
www.americanbankingnews.com - April 28 at 3:48 PM
|PRA Health Sciences, Inc. :PRAH-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017|
finance.yahoo.com - April 28 at 3:18 PM
|Edited Transcript of PRAH earnings conference call or presentation 26-Apr-17 1:00pm GMT|
finance.yahoo.com - April 27 at 10:34 AM
|Research Reports Initiation on Medical Research Stocks -- Alere, OpGen, Novadaq Technologies, and PRA Health|
www.prnewswire.com - April 26 at 5:59 PM
|PRA Health Sciences' (PRAH) CEO Colin Shannon on Q1 2017 Results - Earnings Call Transcript|
seekingalpha.com - April 26 at 5:59 PM
|PRA Health Sciences (PRAH) Receives Daily Media Impact Rating of 0.56|
www.americanbankingnews.com - April 26 at 3:34 PM
|PRA Health Sciences Inc (PRAH) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS|
www.americanbankingnews.com - April 25 at 10:06 PM
|PRA Health Sciences Inc (PRAH) Issues FY17 Earnings Guidance|
www.americanbankingnews.com - April 25 at 7:40 PM
|PRA Health Sciences beats by $0.02, beats on revenue|
seekingalpha.com - April 25 at 6:25 PM
|PRA Health Sciences, Inc. Reports First Quarter 2017 Results|
globenewswire.com - April 25 at 6:25 PM
|PRA Health Sciences beats Street 1Q forecasts|
marketbeat.com - April 25 at 4:47 PM
|PRA Health Sciences Inc (PRAH) Given Consensus Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - April 25 at 12:33 PM
|PRA Health Sciences (PRAH) Receives Daily News Sentiment Rating of 0.44|
www.americanbankingnews.com - April 23 at 12:58 PM
|PRA Health Sciences Inc (PRAH) VP Sells $12,488,630.87 in Stock|
www.americanbankingnews.com - April 19 at 4:52 PM
|PRA Health Sciences (PRAH) Earning Very Positive News Coverage, Report Finds|
www.americanbankingnews.com - April 19 at 10:27 AM
|UnitedHealth (UNH) Poised to Beat on Q1 Earnings: Here's Why|
finance.yahoo.com - April 17 at 6:26 PM
|PRA Health Sciences to Report First Quarter 2017 Earnings|
finance.yahoo.com - April 17 at 6:26 PM
|PRA Health Sciences (PRAH) Receiving Positive Media Coverage, Analysis Finds|
www.americanbankingnews.com - April 14 at 3:46 PM
| Brokerages Anticipate PRA Health Sciences Inc (PRAH) to Post $0.58 EPS|
www.americanbankingnews.com - April 11 at 2:10 PM
|Stocks Flat; Why The Dow 30 Still Looks Solid; 6 Top Medicals To Watch|
finance.yahoo.com - April 7 at 11:59 AM
|PRA Health Sciences Inc (PRAH) Stock Rating Upgraded by Credit Suisse Group AG|
www.americanbankingnews.com - April 2 at 2:54 PM
|PRA Health Sciences Inc (PRAH) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - March 31 at 1:14 PM
|PRA Health Sciences Inc (PRAH) CEO Colin Shannon Sells 50,000 Shares|
www.americanbankingnews.com - March 30 at 7:28 PM
|Insider Selling: PRA Health Sciences Inc (PRAH) Insider Sells 85,182 Shares of Stock|
www.americanbankingnews.com - March 29 at 7:20 PM
|PRA Health Sciences Named Top Workplace in Philadelphia|
finance.yahoo.com - March 27 at 9:39 AM
|PRA Health Sciences' Special Mix Could Have More To Offer|
seekingalpha.com - March 15 at 9:19 AM
|PRA HEALTH SCIENCES, INC. Financials|
finance.yahoo.com - March 1 at 7:34 PM
|PRA Health Sciences, Inc. -- Moody's upgrades PRA Holdings' CFR to Ba3; outlook positive|
www.moodys.com - February 28 at 3:47 PM
|PRA Health Sciences, Inc. Reports Fourth Quarter and Full Year 2016 Results and Provides Q1 and Full Year 2017 ... - Nasdaq|
www.nasdaq.com - February 24 at 8:25 AM
|Edited Transcript of PRAH earnings conference call or presentation 23-Feb-17 2:00pm GMT|
us.rd.yahoo.com - February 24 at 12:25 AM
|PRA Health Sciences' (PRAH) CEO Colin Shannon on Q4 2016 Results - Earnings Call Transcript|
seekingalpha.com - February 23 at 7:24 PM
|PRA HEALTH SCIENCES, INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - February 23 at 7:24 PM
PRA Health Sciences (PRAH) Chart for Thursday, May, 25, 2017